By Fineline Cube Beijing Sinotau International Pharmaceutical Technology Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has approved the clinical trial application for XTR021, a Class 1 innovative radiodrug independently developed by the company for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The 177Lu-labeled radiopharmaceutical targets prostate-specific membrane antigen (PSMA) and demonstrates superior preclinical characteristics compared to existing therapies.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial application approval |
| Product | XTR021 (177Lu-labeled PSMA-targeted radiodrug) |
| Classification | Class 1 innovative drug |
| Indication | Metastatic castration-resistant prostate cancer (mCRPC) |
| Development Stage | Preclinical completed, clinical trials authorized |
Drug Profile & Differentiating Characteristics
XTR021 – Next-Generation Radiopharmaceutical
- Molecule: 177Lu-labeled innovative radiodrug targeting PSMA
- Key Advantages vs. 177Lu-PSMA-617:
- Higher cellular internalization and retention
- Better tumor uptake
- Superior tumor inhibition at significantly lower doses
- Intellectual Property: Independently developed with full rights held by Beijing Sinotau
Clinical Evidence – Investigator-Initiated Trials (IIT)
- Safety Profile: Favorable overall safety with no grade ≥3 adverse events observed
- Key Safety Advantage: No salivary gland toxicity—a common dose-limiting toxicity with current PSMA radiopharmaceuticals
- Efficacy Signal: Rapid and positive PSA50 response rates demonstrated in interim data
- Therapeutic Index: Enhanced efficacy-toxicity ratio suggests potential for improved patient outcomes
Market Opportunity & Competitive Landscape
- mCRPC Burden: Represents advanced stage of prostate cancer with limited treatment options and poor prognosis
- Current Standard: 177Lu-PSMA-617 (Pluvicto) approved globally but limited by toxicity profile and variable response rates
- Addressable Population: Estimated 50,000+ mCRPC patients annually in China with PSMA-positive disease
- Competitive Differentiation: XTR021’s enhanced tumor targeting and reduced toxicity profile positions it as a potential best-in-class radiopharmaceutical
- Strategic Value: First domestically developed PSMA-targeted radiodrug in China, aligning with national priorities for innovative oncology therapeutics
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development and competitive positioning. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, manufacturing scalability, and competitive dynamics in the radiopharmaceutical space.-Fineline Info & Tech